Author:
Reaves Sydney,Hall Katherine C.,Stewart Mary W.,Wentzensen Nicolas,Ferrell Christina,Risley Carolann,Wells Jimmie,Rives Rhonda,Bobo Fajada,Daniels Jon,Farrington Kathy,Morgan Jody C.,Clarke Megan A.
Abstract
Abstract
Purpose
Cervical screening is used to detect and treat precancers to prevent invasive cancers. However, successful prevention also requires adequate follow-up and treatment of individuals with abnormal screening results. The aim was to investigate demographics, clinical characteristics, and follow-up status for individuals needing colposcopy after an abnormal screening result.
Methods
The STRIDES (Studying Risk to Improve DisparitiES) cohort comprises individuals undergoing cervical cancer screening and management at a Mississippi Health Department or University of Mississippi clinic. Follow-up status, demographics, and clinical data were assessed from electronic health records and, if necessary, patient navigation on individuals identified as needing a colposcopy after an abnormal screening.
Results
Of the 1,458 individuals requiring colposcopy, 43.0% had the procedure within 4 months, 16.4% had a delayed procedure, and 39.5% had no documented colposcopy follow-up, with significant predictors of follow-up identified as age and cytology diagnosis. Individuals 30 + were more likely to have follow up with a colposcopy compared to individuals < 30 years (49% and 38.7%, respectively; p < .001). Individuals with cytology diagnoses of LSIL (52.9%), ASC-H (51.4%), and HSIL (62.3%) had higher percentages of adherence to follow-up guidelines (p < .001). In total, we found that 78% of individuals had some type of follow-up, including a repeat screening visit.
Conclusion
Despite high cervical cancer screening rates among Mississippians, a substantial proportion did not have adequate next-step intervention. However, it is encouraging that highest risk individuals were more likely to have a colposcopy. Regardless, continuing to understand the underlying causes for incomplete follow-up is crucial for timely secondary targeted interventions to reduce cervical cancer burden, promote awareness, and improve health outcomes.
Funder
Intramural Research Program of the National Cancer Institute including funding from the Cancer Cures Moonshot Initiative
Dr. Carolann Risley is supported by the National Institute of General Medical Sciences of the National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Yang DX, Soulos PR, Davis B, Gross CP, Yu JB (2018) Impact of widespread cervical cancer screening. Am J Clin Oncol 41(3):289–294. https://doi.org/10.1097/coc.0000000000000264
2. American Cancer Society. (2024). Cancer Facts & Figures 2024. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf
3. Centers for Disease Control and Prevention. (n.d.). Cervical Cancer is Preventable. Centers for Disease Control and Prevention.
4. Liang LA, Zeissig SR, Schauberger G, Merzweiler S, Radde K, Fischbeck S, Ikenberg H, Blettner M, Klug SJ (2022) Colposcopy non-attendance following an abnormal cervical cancer screening result: a prospective population-based cohort study. BMC Women’s Health. https://doi.org/10.1186/s12905-022-01851-6
5. Risley C, Stewart MW, Geisinger KR, Hiser LM, Morgan JC, Owens KJ, Ayyalasomayajula K, Rives RM, Jannela A, Grunes DE, Zhang L, Schiffman M, Wentzensen N, Clarke MA (2021) Strides—studying risk to improve disparities in cervical cancer in Mississippi—design and baseline results of a statewide cohort study. Prev Med 153:106740. https://doi.org/10.1016/j.ypmed.2021.106740